Lit­tle Cara steers through their first pos­i­tive PhI­II with a ‘break­through’ drug and a path to the FDA

Cara Ther­a­peu­tics $CARA has suc­cess­ful­ly hit a key mile­stone in its push to get their lead drug across the fin­ish line at the FDA. The biotech says it racked up a set of clear­ly pos­i­tive da­ta for their one drug, Ko­r­su­va (CR845), in their first Phase III tri­al read­out for a se­vere itch­ing con­di­tion among pa­tients on he­modial­y­sis. And if they can do it again in a con­fir­ma­to­ry Phase III due out lat­er in the year, they’ll be ready to beat a trail to reg­u­la­tors in search of an OK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER